A Recent Study Compared The Efficacy and Safety of Biosimilar-Infliximab and Originator-Infliximab in Combination with Methotrexate for Active Rheumatoid Arthritis

Primary tabs

NEWS
A Recent Study Compared The Efficacy and Safety of Biosimilar-Infliximab and Originator-Infliximab in Combination with Methotrexate for Active Rheumatoid Arthritis

Korean Scientists Bae SC and Lee YH carried out the Bayesian network meta-analysis in which they combined the direct and indirect evidence from various randomized controlled trials (RCTs) examining the safety and efficacy of biosimilar + MTX and infliximab + MTX and placebo + MTX (MTX group) in patients with active RA despite treatment with MTX.

Seven RCTs involving 2606 patients were included in the study. The American College of Rheumatology (ACR)20 response were evaluated. It was found that ACR20 response rate was significantly higher in the biosimilar + MTX group than in the MTX group with reported odds ratio (OR) 3.31, 95% credible interval (CrI) 1.74-6.06. The ACR20 response rate was also significantly higher in the infliximab + MTX group than in the MTX group with OR 3.15, 95% CrI 1.99-4.70. No difference was reported in the ACR20 response rate between the biosimilar+ MTX and infliximab + MTX groups. The surface under the cumulative ranking curve (SUCRA) based ranking probability indicated that treatment with biosimilar + MTX has the highest probability of achieving the ACR20 response rate with SUCRA = 0.7964, followed by infliximab + MTX with SUCRA = 0.7018) and MTX alone with SUCRA = 0.0018. But the ACR50 and ACR70 response rates showed similar distribution pattern to ACR20 response rate.

Moreover, the number of serious adverse events (SAEs) did not differ significantly among the three interventions.

The biosimilar- and originator-infliximab, in combination with MTX, did not show any significant difference regarding efficacy and safety, which means both the combinations represent effective interventions for active RA, with a low risk of SAEs.

Source:                       

Int J Rheum Dis.

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/29671942

The original title of the article:

Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials

Authors

Bae; S. C. et al.

SearchTags: 
Therapeutic, infliximab, Biosimilar, rheumatoid arthritis, meta-analysis, randomized controlled, Efficacy, Safety, SUCRA.
Log in or register to post comments